6月24日，uniQure盘中上涨8.4%，报48.12美元/股，成交额9266.41万美元。
消息面上，公司于6月23日宣布启动1.5亿美元承销公开发行，并向承销商提供最多2250万美元的超额配售选择权。市场将此次融资视为公司推进BLA提交的积极信号。此前6月17日，FDA确认其亨廷顿病基因疗法AMT-130的I/II期三年数据可作为加速批准BLA的主要依据，公司计划第三季度提交申请。加拿大皇家银行已将目标价从35美元上调至65美元，给予获批概率75%。本次融资为后续商业化储备资金，延续了FDA监管立场反转后的上行动能。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.